RxDoctor Payments Data

Mychael Luu, MD

Dermatology · San Jose, CANPI 1093718546

Payments from drug & device makers

$35,022in general payments, 2019–2025

Across 1,346 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • Lilly USA, LLC$2K
  • Novartis$2K
  • LEO Pharma Inc.$2K
  • plus $17K from 33 others

What the payments were for

  • Speaking & faculty fees$3501%
  • Food & beverage$33,33895%
  • Education$1,3344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,022 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$301,238
Medicare patients
440
Services billed
2,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab204$814,235
SkyriziRisankizumab-Rzaa37$760,488
Cosentyx Sensoready (2 Pens)Secukinumab44$317,631
Cosentyx Unoready PenSecukinumab22$220,322
AdbryTralokinumab-Ldrm41$170,241
Taltz AutoinjectorIxekizumab16$146,948
Taltz SyringeIxekizumab12$94,745
OtezlaApremilast16$77,257
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc202$8,208
Clobetasol Propionate180$7,959
Calcipotriene28$7,203
Fluocinonide141$6,444
Pimecrolimus33$6,117
Tacrolimus32$4,879
Ketoconazole223$3,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$4,376$760,48837 claims
LEO Pharma Inc.Adbry$2,092$170,24141 claims
AmgenOtezla$939$77,25716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →